Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Cancer detection can help revive non-toxic treatment

Cancer detection can help revive non-toxic treatment

Researchers at the University of Virginia have published a new study that could revive once promising treatments that help fight solid cancerous tumors, the university announced Monday. cancer, succeeded in laboratory tests but failed in human trials. Lead researcher Jogender Tushir-Singh of UVA School Medicine’s Department of Biochemistry and Molecular Genetics says the new findings could help restart human trials after new success in laboratory models. “By far, researchers and protein engineers across the globe, including our research team, were focused on supercharging and superactivating tumor cell death receptors targeted at antibodies in the fight against cancer,”

; Tushir-Singh said. Here at UVA, we took a comprehensive approach to harnessing the power of the immune system to create dual-specificity and potentially clinically effective oncological drugs for solid tumors. “

“Our findings also have significant potential to further enhance the clinical efficacy of currently FDA-approved PD-L1 targeting antibodies in solid tumors, particularly those approved for lethal triple negative breast cancer,” Tushir-Singh added. Researchers first developed an approach that selectively uses antibodies to target the cancer cell’s surface called death receptor-5 (DR5). The treatment has been successful in clinical trials in the past and has effectively reduced tumor size in animal experiments. However, when treatment reached human clinical trials, “these antibodies could not consistently improve patient survival.” Tushir-Singh and his team found that “the anti-DR5 antibody approaches unintentionally triggered biological processes that suppress the body’s immune response,” the university explained in a statement that allowed the cancer cells to bypass treatment and continue to grow.

The research shares results that could restore the effectiveness of the treatment by combating the biological process, which has so far been shown to be successful in shrinking tumors and improving the survival of laboratory mice. “We would like to see these strategies in clinical trials, which we strongly believe have great potential in solid tumors,” said Tushir-Singh. “Our results are extraordinary: together with the translational effect, our work after more than 60 years of research in the field explains why most approaches aimed at apoptosis [cell death] have not performed well in clinical trials and eventually developed resistance to therapies. ”

Source link